著者

齋藤 佳敬 山田 武宏 小林 正紀 榊原 純 品川 尚文 木下 一郎 秋田 弘俊 井関 健

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.139, no.12, pp.1601-1608, 2019-12-01 (Released:2019-12-01)

参考文献数

20

被引用文献数

1

---

Paclitaxel (PTX)-associated acute pain syndrome (P-APS) is characterized by disabling but transient arthralgia and myalgia in up to 80% of patients administered with PTX. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely administered to patients with cancer who have pain or fever, and are mainly used to manage P-APS. In this study, we investigated how P-APS appear in the patients who were administered NSAIDs prior to PTX injection. The incidence or severity and duration of P-APS in patients previously administered NSAIDs were compared to those of patients who were not administered NSAIDs. The relationship between previously administered NSAIDs and rescue administration for the relief of P-APS was also evaluated. It was revealed that the incidence and duration of P-APS were 72% and 4.67±2.30 d, respectively, in the control group and 84% and 6.19±3.30 d, respectively, in the NSAIDs group. There was no significant difference in the incidence and duration and the severity of P-APS between the two groups. Patients who were previously administered NSAIDs tended to obtain less pain relief from NSAIDs administered as rescue medications, and needed other medication. Univariate and multivariate analysis revealed no correlation between previously administered NSAIDs or patient characteristics and the incidence of P-APS. In this study, it was found that clinical condition that needs NSAIDs and previously administered NSAIDs prior to PTX injection do not affect the incidence, severity, and duration of P-APS. These results will help in educating patients about their medications and will contribute to the management of P-APS.

著者

畑中 豊 木下 一郎 秋田 弘俊

出版者

特定非営利活動法人 日本肺癌学会

雑誌

肺癌 (ISSN:03869628)

巻号頁・発行日

vol.62, no.1, pp.15-25, 2022-02-20 (Released:2022-02-25)

参考文献数

19

被引用文献数

1 1

---

肺癌におけるドライバー変異を対象としたバイオマーカー検査は,EGFR,ALK,ROS1,BRAF,METに,2021年にRETが新たに加わり,現在本邦では6遺伝子がコンパニオン診断(CDx)項目となっている.またがん免疫療法のバイオマーカー検査としてPD-L1 IHC検査が,2016年よりCDxとして実施されるようになった.本稿では,これらバイオマーカー検査の臨床導入の経緯やその際に直面した諸課題について総括するとともに,マルチプレックスアッセイやリキッドバイオプシーなどの新規検査技術のさらなる普及が見込まれている肺癌CDxの今後の展開について概説する.